San Diego, CA —. Binding Site’s Immunologicals Group is pleased to announce the addition of a number of new monoclonal antibodies to be used in research and IVD manufacturing applications involving Hepatitis B Surface Antigen (HBsAg). All of these monoclonal antibodies have been expressly designed for use as an integral component within solid phase enzyme immunoassay test procedures, especially ELISAs.
Hepatitis B is an infectious disease caused by the Hepatitis B Virus (HBV) that affects the liver, causing both acute and chronic infections. A number of markers are available to aid the identification and management of Hepatitis B. The introduction of these products will further aid in the identification and management of the disease.
Currently available monoclonals to HBsAg include those targeted toward HBsAg 'a' 18.104.22.168; HBsAg 'a' 25; HBsAg 'a' S1.9; HBsAg 'a' S2 A13; HBsAg 'a' S2 B3; HBsAg 'a' S3; HBsAg 'a' S2 7A; HBsAg 'd' AD1; and HBsAg 'y' AY1. All of these monoclonal antibodies are sourced from mice and manufactured to a purity level of > 95%. In addition, they are supplied preservative-free, demonstrate exceptional lot-to-lot consistencies, and feature an outstanding shelf life stability claim of four years from the date of manufacture. All are conveniently packaged in a standard sized 1.0mg filled vial with larger, bulk configurations also available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and academic | clinical | biopharmaceutical | life-science research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.